These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15999217

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z, 037 Study Group.
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [Abstract] [Full Text] [Related]

  • 25. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study.
    Song M, Kim JH, Lee KS, Lee JZ, Oh SJ, Seo JT, Choi JB, Kim SW, Rhee SJ, Choo MS.
    Int J Clin Pract; 2015 Feb; 69(2):242-50. PubMed ID: 25363415
    [Abstract] [Full Text] [Related]

  • 26. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z.
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Darifenacin: Pharmacology and clinical usage.
    Steers WD.
    Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR, Toglia MR, Forero-Schwanhaeuser S, He W.
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [Abstract] [Full Text] [Related]

  • 35. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
    But I, Goldstajn MS, Oresković S.
    Coll Antropol; 2012 Dec; 36(4):1347-53. PubMed ID: 23390832
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.
    Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G, Delconte A.
    Int J Clin Pract; 2008 Apr; 62(4):606-13. PubMed ID: 18324952
    [Abstract] [Full Text] [Related]

  • 38. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D, Khullar V, Michel MC, Morrow JD, Sun F, Guan Z, Dmochowski R.
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
    Oresković S, But I, Banović M, Goldstajn MS.
    Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.